Table of contents
- Brexit
- Brexit update from the MHRA
- Guidance released for stakeholders on post-Brexit human and veterinary medicines
- Research and development
- Evidence submitted to committee on genomics in the NHS
- House of Lords Committee takes evidence on life sciences
- Manufacture, marketing and sale
- Transitional monitoring arrangements for MAHs
- MHRA launches new online service
- Updated manual on 'borderline' products in medical device regulatory framework published
More sections of this document available when you sign-in to Lexis+ or register for a free trial.
Article summary
This week’s edition of Life Sciences highlights includes updates from the Medicines and Healthcare products Regulatory Agency and the Irish Health Products Regulatory Authority on Brexit, an analysis on the decision in Teva v AstraZeneca and the European Commission’s announcement on the patient data exchange infrastructure.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial